Due to aberrant CDK2 activity in other cancers including ovarian cancer, Hepatocellular carcinoma, glioblastoma, prostate cancer, and B cell lymphoma9, it is highly possible that HHT could also have the anti-tumor effects in these cancers in addition to leukemia. Here, CDK2 is linked to hepatocellular carcinoma.